UNSPSC 51352210: Hexestrol diphosphate

This classification denotes a non-steroidal estrogen C18H24O8P2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 30L14W008X, chemically known as hexestrol 4,4'-diphosphoric ester, but more generally known as hexestrol diphosphate, which bears US NIH Compound Identifier 193055. Most nations, for tariff and trade purposes, schedule hexestrol diphosphate under HS 29072900 and SITC 51243. As of Q4 2014, HEXESTROL DIPHOSPHATE remains US FDA's Preferred Term for this commodity.

SMILES: CC[C@H](C1CCC(CC1)OP(=O)(O)O)[C@@H](CC)C2CCC(CC2)OP(=O)(O)O.

UNSPSC 51352210 Hexestrol diphosphate is a Commodity code that encompasses individual pharmaceutical products supplied through state and local cooperative purchasing agreements for distribution to government healthcare facilities. The code captures hexestrol diphosphate and similar generic pharmaceuticals procured by state agencies and their participating municipal and county partners through multistate cooperative contracts rather than individual direct purchases. State and local buyers under this code acquire these products via established pharmaceutical wholesaler channels to support clinical and institutional healthcare delivery, with procurement typically structured as framework agreements that lock in pricing and supply terms across multiple jurisdictions and facilities over a contract term.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities, including Oregon. Vendors must supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and demonstrate cGMP certification, Drug Supply Chain Security Act (DSCSA) compliance, and contractual relationships with at least two of the three authorized wholesalers with functioning chargeback systems. Evaluation is weighted primarily on price competitiveness (75 percent), with smaller weights assigned to fixed pricing, administrative compliance, EDI capability, and agreement to a 3 percent administrative fee. The contract term runs two years for new responders with optional extensions, and vendors must maintain comprehensive insurance including $5 million commercial general liability and $2 million network security and privacy liability.